Abstract
Despite substantial progress that has been made in understanding many aspects regarding biology and pathogenesis of human immunodeficiency virus type 1 (HIV-1), there is currently no vaccine or curative treatment available. HIV-1 continues to be a major global health problem. In this regard, new strategies are required for promoting a complete immune reconstitution and eradicating the virus from the body. The rationale for the use of hematopoietic stem cell (HSC)-based gene therapy against HIV infection is that, after transplantation, genetically modified HSCs carrying anti-HIV transgenes would engraft, divide and differentiate into large numbers of mature myeloid and lymphoid cells that express antiviral genes and thus are protected from HIV invasion or productive replication. HIV-1 attachment to susceptible cells involves binding of gp120 to CD4 receptor and subsequently to a HIV co-receptor, either CCR5 or CXCR4. The pivotal role of CCR5 in HIV-1 acquisition and disease progression has been established by the discovery of a naturally occurring 32-bp deletion in CCR5 (CCR5Δ32) which generates a nonfunctional gene product. Homozygosity for CCR5Δ32 confers profound resistance against HIV infection, and heterozygous mutation that induces a decrease in CCR5 surface expression is associated with lower plasma viral load and delayed progression to acquired immune deficiency syndrome (AIDS). This, together with the fact of R5 dominance during the acute and asymptomatic phase, suggests that CCR5 is an attractive target for HIV gene therapeutics. The present review addresses recent advances of CCR5-targeted HSC gene approaches to treat HIV infection, discusses the future prospects and postulates potential strategies in the field.
Keywords: CCR5Δ32, gene therapy, hematopoietic stem cell, HIV-1, induced pluripotent stem cell, zinc-finger nucleases
Current Stem Cell Research & Therapy
Title:CCR5-Targeted Hematopoietic Stem Cell Gene Approaches for HIV Disease: Current Progress and Future Prospects
Volume: 7 Issue: 4
Author(s): Yu Lai
Affiliation:
Keywords: CCR5Δ32, gene therapy, hematopoietic stem cell, HIV-1, induced pluripotent stem cell, zinc-finger nucleases
Abstract: Despite substantial progress that has been made in understanding many aspects regarding biology and pathogenesis of human immunodeficiency virus type 1 (HIV-1), there is currently no vaccine or curative treatment available. HIV-1 continues to be a major global health problem. In this regard, new strategies are required for promoting a complete immune reconstitution and eradicating the virus from the body. The rationale for the use of hematopoietic stem cell (HSC)-based gene therapy against HIV infection is that, after transplantation, genetically modified HSCs carrying anti-HIV transgenes would engraft, divide and differentiate into large numbers of mature myeloid and lymphoid cells that express antiviral genes and thus are protected from HIV invasion or productive replication. HIV-1 attachment to susceptible cells involves binding of gp120 to CD4 receptor and subsequently to a HIV co-receptor, either CCR5 or CXCR4. The pivotal role of CCR5 in HIV-1 acquisition and disease progression has been established by the discovery of a naturally occurring 32-bp deletion in CCR5 (CCR5Δ32) which generates a nonfunctional gene product. Homozygosity for CCR5Δ32 confers profound resistance against HIV infection, and heterozygous mutation that induces a decrease in CCR5 surface expression is associated with lower plasma viral load and delayed progression to acquired immune deficiency syndrome (AIDS). This, together with the fact of R5 dominance during the acute and asymptomatic phase, suggests that CCR5 is an attractive target for HIV gene therapeutics. The present review addresses recent advances of CCR5-targeted HSC gene approaches to treat HIV infection, discusses the future prospects and postulates potential strategies in the field.
Export Options
About this article
Cite this article as:
Lai Yu, CCR5-Targeted Hematopoietic Stem Cell Gene Approaches for HIV Disease: Current Progress and Future Prospects, Current Stem Cell Research & Therapy 2012; 7 (4) . https://dx.doi.org/10.2174/157488812800793108
DOI https://dx.doi.org/10.2174/157488812800793108 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aerosol Delivery in the Treatment of Lung Cancer
Current Cancer Drug Targets Omalizumab: Not Only For Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Clinical Immunotherapy of B-Cell Malignancy Using CD19-Targeted CAR T-Cells
Current Gene Therapy Therapeutic Outlook of Pyrazole Analogs: A Mini Review
Mini-Reviews in Medicinal Chemistry Thrombospondin and Apoptosis: Molecular Mechanisms and Use for Design of Complementation Treatments
Current Drug Targets Design, Synthesis and Bioactivities of Phenylamino-Pyrimidine Derivatives as Novel Protein Tyrosine Kinase Inhibitors
Letters in Drug Design & Discovery Behavioral Tasks Evaluating Schizophrenia-like Symptoms in Animal Models: A Recent Update
Current Neuropharmacology Clear Cell Renal Cell Cancer Tumor-Propagating Cells: Molecular Characteristics
Current Signal Transduction Therapy Aliphatic and Aromatic Oxidations, Epoxidation and S-Oxidation of Prodrugs that Yield Active Drug Metabolites
Current Medicinal Chemistry Traditional Chinese Medicine Remedy to Jury: The Pharmacological Basis for the Use of Shikonin as an Anticancer Therapy
Current Medicinal Chemistry NBS1 Heterozygosity and Cancer Risk
Current Genomics PIM1 Kinase as a Target in Prostate Cancer: Roles in Tumorigenesis, Castration Resistance, and Docetaxel Resistance
Current Cancer Drug Targets Resveratrol and Its Analogues: Promising Antitumor Agents
Anti-Cancer Agents in Medicinal Chemistry Novel Mechanisms of Anticancer Activities of Green Tea Component Epigallocatechin- 3-Gallate
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Biological Activity of Chiral Dihydropyrazole: Potential Lead for Drug Design
Mini-Reviews in Medicinal Chemistry Potential Health Benefits of Berries
Current Nutrition & Food Science Cell Surface Nucleolin as a Target for Anti-Cancer Therapies
Recent Patents on Anti-Cancer Drug Discovery Editorial (Thematic Issue: Clonal Heterogeneity and Diversification in B-cell Disorders)
Current Cancer Therapy Reviews Polyphenols as Potential Therapeutics for Pain and Inflammation in Spinal Cord Injury
Current Molecular Pharmacology Effects of Elicitors, Viticultural Factors, and Enological Practices on Resveratrol and Stilbenes in Grapevine and Wine
Mini-Reviews in Medicinal Chemistry